Find Reports
Select Report Type
Reimbursement Review
Displaying 1126 - 1150 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| isatuximab | Sarclisa | isatuximab | multiple myeloma not eligible for ASCT | Active | PC0378-000 | ||||
| delgocitinib | TBC | delgocitinib | Chronic hand eczema | Received | SR0875-000 | ||||
| Pharmaceutical Reviews Update ... | |||||||||
| durvalumab | Imfinzi | durvalumab | limited-stage small cell lung cancer (LS-SCLC) | Active | PC0389-000 | ||||
| amivantamab | Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Active | PC0393-000 | ||||
| lazertinib and amivantamab | Lazcluze and Rybrevant | lazertinib and amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Active | PC0392-000 | ||||
| pembrolizumab | Keytruda | pembrolizumab | Advanced or recurrent endometrial carcinoma | Active | PC0383-000 | ||||
| leuprolide mesylate | Camcevi | leuprolide mesylate | Prostate cancer | Active | PC0370-000 | ||||
| datopotamab deruxtecan | TBC | datopotamab deruxtecan | advanced or metastatic non-squamousnon-small cell lung cancer (NSCLC) | Cancelled | PC0384-000 | ||||
| belzutifan | Welireg | belzutifan | advanced renal cell carcinoma (RCC) | Active | PC0386-000 | ||||
| pembrolizumab | Keytruda | pembrolizumab | Advanced or metastatic malignant pleural mesothelioma | Active | PC0387-000 | ||||
| polatuzumab vedotin | Polivy | polatuzumab vedotin | Large B-cell lymphoma | Active | PC0397-000 | ||||
| Dabrafenib trametinib | N/A | Dabrafenib trametinib | Head and neck cancer | Active | PX0373-000 | ||||
| Fampridine | Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Withdrawn | SR0404-000 | ||||
| Vortioxetine | Trintellix | Vortioxetine | Depression, major depressive disorder | Withdrawn | SR0402-000 | ||||
| Propranolol | Hemangiol | Propranolol | Infantile hemangioma | Withdrawn | SR0411-000 | ||||
| Tedizolid phosphate | Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | SR0413-000 | ||||
| Palonosetron | Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | SR0415-000 | ||||
| Eculizumab | Soliris | Eculizumab | Atypical hemolytic uremic syndrome | N/A | Complete | SF0416-000 | |||
| Solifenacin succinate / tamsul... | VesiFlow | Solifenacin succinate / tamsulosin hydrochloride | Benign prostatic hyperplasia | Withdrawn | SR0424-000 | ||||
| dabrafenib trametinib | TBC | dabrafenib trametinib | Pediatric low grade glioma (ped LGG) | Active | PX0375-000 | ||||
| pemigatinib | Pemazyre | pemigatinib | Cholangiocarcinoma | Active | PC0391-000 | ||||
| regorafenib | N/A | regorafenib | Metastatic osteosarcoma | Active | PX0374-000 | ||||
| bimekizumab | Bimzelx | bimekizumab | Hidradenitis suppurative | Active | SR0856-000 | ||||
| cipaglucosidase alfa with migl... | Pombiliti with Opfolda | cipaglucosidase alfa with miglustat | Pompe disease | Active | SR0871-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1126 - 1150 of 2138
Please scroll or swipe to the right to view the full content.
Provisional Funding Algorithm
Displaying 76 - 81 of 81